Sugi Predict

Sugi Predict / Compounds / SCHEMBL18817005

SCHEMBL18817005

SCHEMBL18817005

COC(=O)c1c(N)nc2ccc(Cl)nn12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 3/20 0.51
▸ DYRK1A Q13627 3/20 0.51
▸ DYRK1B Q9Y463 3/20 0.51
▸ ABL1 P00519 2/20 0.51
▸ CDK9 P50750 2/20 0.51
▸ DAPK3 O43293 1/20 0.51
▸ JAK2 O60674 1/20 0.51
▸ PRKD3 O94806 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ CSF1R P07333 1/20 0.51
▸ RET P07949 1/20 0.51
▸ MET P08581 1/20 0.51
▸ PDGFRA P16234 1/20 0.51
▸ PRKACA P17612 1/20 0.51
▸ LTK P29376 1/20 0.51
▸ GRK5 P34947 1/20 0.51
▸ KDR P35968 1/20 0.51
▸ MAPK8 P45983 1/20 0.51
▸ MAPK9 P45984 1/20 0.51
▸ CSNK1A1 P48729 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18817185 0.84 DAPK3 (0.52) CDK5DYRK1ADYRK1BABL1CDK9
SCHEMBL18816951 0.82 ALDH1A1 (0.40) CDK5DYRK1ADYRK1BABL1CDK9
SCHEMBL16764299 0.80 MAPK8 (0.48) CDK5DYRK1ADYRK1BABL1CDK9
SCHEMBL15548631 0.75 ALDH1A1 (0.45) F2NTRK1SMN1; SMN2KDM4EALDH1A1
SCHEMBL16598434 0.74 KDM4E (0.49) SMN1; SMN2KDM4EALDH1A1L3MBTL1MEN1
SCHEMBL956476 0.72 ALDH1A1 (0.43) CDK5DYRK1ADYRK1BCDK9CSF1R
SCHEMBL3486356 0.72 KDM4E (0.44) CDK5DYRK1ADYRK1BCDK9NTRK1
SCHEMBL18817149 0.71 FYN (0.46) CDK5DYRK1ADYRK1BABL1CDK9
SCHEMBL16947087 0.71 TNF (0.47) CDK5DYRK1ADYRK1BCDK9MAPK1
SCHEMBL953671 0.70 MAPK1 (0.52) MAPK1SMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116829562-B Macrocyclic compound, pharmaceutical composition and application thereof 深圳国顺康医药科技有限公司 2025-04-01 — — CN disclosed
US-20240132517-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF GOHARMONY THERAPEUTICS (SHENZHEN) CO., LTD. (CN) 2024-04-25 — — US disclosed
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2023-10-03 — — US disclosed
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2023-10-03 — — US disclosed
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2023-10-03 — — US disclosed
CN-116829562-A Macrocyclic compound, pharmaceutical composition and application thereof 深圳国顺康医药科技有限公司 2023-09-29 — — CN disclosed
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2023-01-12 — — US disclosed
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2023-01-12 — — US disclosed
EP-4086259-A1 HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2022-11-09 — — EP disclosed
WO-2022171139-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 北京国鸿生物医药科技有限公司 2022-08-18 — — WO disclosed
US-20200031837-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-01-30 — — US disclosed
US-10472368-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2019-11-12 — — US disclosed
US-10472368-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2019-11-12 — — US disclosed
EP-3371190-A1 HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2018-09-12 — — EP disclosed
US-10065963-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2018-09-04 — — US disclosed
US-20170129899-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2017-05-11 — — US disclosed
US-20170129899-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2017-05-11 — — US disclosed
WO-2017079519-A1 HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2017-05-11 — — WO disclosed
WO-2017079519-A1 HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2017-05-11 — — WO disclosed
US-20170129899-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2017-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors PIK3CD, PIK3CG, PIK3R5 CDK5 256/4885DYRK1A 3876/4885DYRK1B 3829/4885
US-10472368-B2 Heterocyclic compounds as PI3K-γ inhibitors PIK3CD, PIK3CG, PIK3R5 CDK5 256/4885DYRK1A 3876/4885DYRK1B 3829/4885
US-10065963-B2 Heterocyclic compounds as PI3K-γ inhibitors PIK3CD, PIK3CG, PIK3R5 CDK5 256/4885DYRK1A 3876/4885DYRK1B 3829/4885
US-20200031837-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD CDK5 312/4885DYRK1A 1739/4885DYRK1B 1724/4885
US-20170129899-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD CDK5 312/4885DYRK1A 1739/4885DYRK1B 1724/4885
US-20240132517-A1 MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF SRC, FLT3, BRAF CDK5 292/4885DYRK1A 281/4885DYRK1B 255/4885
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD CDK5 312/4885DYRK1A 1739/4885DYRK1B 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.